CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTP53P72RPrognosticDoes Not SupportPoor OutcomeCervical CancerKlug et al., 2001
DBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponsePancreatic CancerMitomycinvan der Heijden et al., 2005
DPDGFRAI843DELPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
BRB1EXPRESSIONPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaZhao et al., 2012
BCDKN2Ap16 ExpressionPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaZhao et al., 2012
BMLH1METHYLATIONPredictiveSupportsResistanceStomach CarcinomaOxaliplatinLi et al., 2015
BPTPN11OverexpressionPrognosticSupportsPoor OutcomeLaryngeal CarcinomaGu et al., 2014
DMTORS2215YPredictiveSupportsSensitivity/ResponseEndometrial AdenocarcinomaSirolimusGrabiner et al., 2014
DMTORC1483YPredictiveSupportsSensitivity/ResponseT-cell Acute Lymphoblastic LeukemiaSirolimusGrabiner et al., 2014
DMTORE1799KPredictiveSupportsSensitivity/ResponseClear Cell Renal Cell CarcinomaSirolimusGrabiner et al., 2014
DRB1OverexpressionPredictiveSupportsResistancePancreatic AdenocarcinomaMitomycin,Doxorubicin,Fluorouracil,GemcitabinePlath et al., 2002
DEML4::ALKFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLorlatinibInfarinato et al., 2016
DEML4::ALKFusion AND ALK F1245CPredictiveSupportsResistanceCancerCrizotinibZhang et al., 2011
CEML4::ALKFusion AND ALK F1245CPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKodityal et al., 2016
DEML4::ALKFusion AND ALK S1206YPredictiveSupportsSensitivity/ResponseCancerCeritinibFriboulet et al., 2014
DEML4::ALKFusion AND ALK T1151dupPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTanespimycinKatayama et al., 2012
DEML4::ALKFusion AND ALK G1202RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTanespimycinKatayama et al., 2012
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseCancerBrigatinibFontana et al., 2015
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseCancerCeritinibFontana et al., 2015
DNPM1::ALKFusionPredictiveSupportsSensitivity/ResponseCancerCrizotinibFontana et al., 2015
DPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseCancerTanespimycin,PictilisibWirtz et al., 2015
DPTENMutationPredictiveDoes Not SupportSensitivity/ResponseHead And Neck CancerPictilisib,TanespimycinWirtz et al., 2015
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerDactolisibLui et al., 2013
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerCetuximab,DactolisibLui et al., 2013
DPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseHead And Neck CancerPictilisib,Tanespimycin,TrametinibWirtz et al., 2015
CALKI1171PredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinibOu et al., 2015
DCDKN2ALossPredictiveSupportsSensitivity/ResponseSkin MelanomaAlvocidibRobinson et al., 2003
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerA66Utermark et al., 2012
DPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBerns et al., 2007
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBerns et al., 2007
CMETAmplificationPredictiveSupportsResistanceLung AdenocarcinomaErlotinib,GefitinibYu et al., 2013
CEGFRS768IPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibMasago et al., 2010
BBRAFV600PredictiveSupportsSensitivity/ResponseColorectal CancerTrametinib,DabrafenibCorcoran et al., 2015
DSF3B1K700EPredictiveSupportsSensitivity/ResponseBreast CancerSpliceostatin AMaguire et al., 2015
DSF3B1K666NPredictiveSupportsSensitivity/ResponseBreast CancerSpliceostatin AMaguire et al., 2015
CKITM541LPredictiveSupportsSensitivity/ResponseChronic LeukemiaImatinibIurlo et al., 2014
CMTORE2014K AND MTOR E2419KPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaEverolimus,PazopanibWagle et al., 2014
CRICTORAmplificationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaOnatasertib,SapanisertibCheng et al., 2015
CFIP1L1::PDGFRAFusion AND PDGFRA T674IPredictiveSupportsResistanceMyeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1ImatinibCools et al., 2003
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabSerra et al., 2008
DBRAFL597RPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenib,TrametinibDahlman et al., 2012
DBRAFL597SPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenib,TrametinibDahlman et al., 2012
DBRAFL597QPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinib,VemurafenibDahlman et al., 2012
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaTaselisibZumsteg et al., 2016
DNF1MutationPredictiveSupportsResistanceSkin MelanomaVemurafenibMaertens et al., 2013
DNF1MutationPredictiveSupportsSensitivity/ResponseSkin MelanomaVTX-11e,AZ628Whittaker et al., 2013
BNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaBinimetinibAscierto et al., 2013
CNRASQ61PredictiveSupportsSensitivity/ResponseSkin MelanomaSelumetinibAdjei et al., 2008
DNRASQ61KPredictiveSupportsResistanceSkin MelanomaVemurafenibAtefi et al., 2011
DNRASQ61KPredictiveSupportsSensitivity/ResponseSkin MelanomaSelumetinibAtefi et al., 2011
Page 71 of 96
PreviousNext